A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Pfizer
Onconic Therapeutics Inc.
Qilu Pharmaceutical Co., Ltd.
Second Life Therapeutics
Suzhou Transcenta Therapeutics Co., Ltd.
GE Healthcare
Base Therapeutics (Shanghai) Co., Ltd.
RemeGen Co., Ltd.
Beijing Biostar Pharmaceuticals Co., Ltd.
Danatlas Pharmaceuticals Co., Ltd